Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Journal of Proteome Research
|
January 26, 2010
Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry
Cloud P Paweletz, Matthew C Wiener, Andrey Y Bondarenko, et al.
Plos One
|
May 2, 2015
Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models
Sethu Sankaranarayanan, Donna M Barten, Laurel Vana, et al.
Chemmedchem
|
December 17, 2008
Evolution of tertiary carbinamine BACE-1 inhibitors: Abeta reduction in rhesus CSF upon oral dosing
Philippe G Nantermet, Hemaka A Rajapakse, Mathew G Stanton, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 8, 2007
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors
Stacey R Lindsley, Keith P Moore, Hemaka A Rajapakse, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 25, 2012
Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027
Donna M Barten, Patrizia Fanara, Cathy Andorfer, et al.
Journal of Medicinal Chemistry
|
September 25, 2008
Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase
James C Barrow, Shaun R Stauffer, Kenneth E Rittle, et al.
Journal of Alzheimer'S Disease : JAD
|
April 27, 2005
Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells
Xiao-Ping Shi, Katherine Tugusheva, James E Bruce, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 22, 2015
Methyl-substitution of an iminohydantoin spiropiperidine β-secretase (BACE-1) inhibitor has a profound effect on its potency
Melissa Egbertson, Georgia B McGaughey, Steven M Pitzenberger, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 1, 2013
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat
Charles F Albright, Randy C Dockens, Jere E Meredith, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 16, 2008
First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates
Sethu Sankaranarayanan, Marie A Holahan, Dennis Colussi, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Journal of Proteome Research
|
January 26, 2010
Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry
Cloud P Paweletz, Matthew C Wiener, Andrey Y Bondarenko, et al.
Plos One
|
May 2, 2015
Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models
Sethu Sankaranarayanan, Donna M Barten, Laurel Vana, et al.
Chemmedchem
|
December 17, 2008
Evolution of tertiary carbinamine BACE-1 inhibitors: Abeta reduction in rhesus CSF upon oral dosing
Philippe G Nantermet, Hemaka A Rajapakse, Mathew G Stanton, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 8, 2007
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors
Stacey R Lindsley, Keith P Moore, Hemaka A Rajapakse, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 25, 2012
Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027
Donna M Barten, Patrizia Fanara, Cathy Andorfer, et al.
Journal of Medicinal Chemistry
|
September 25, 2008
Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase
James C Barrow, Shaun R Stauffer, Kenneth E Rittle, et al.
Journal of Alzheimer'S Disease : JAD
|
April 27, 2005
Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells
Xiao-Ping Shi, Katherine Tugusheva, James E Bruce, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 22, 2015
Methyl-substitution of an iminohydantoin spiropiperidine β-secretase (BACE-1) inhibitor has a profound effect on its potency
Melissa Egbertson, Georgia B McGaughey, Steven M Pitzenberger, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 1, 2013
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat
Charles F Albright, Randy C Dockens, Jere E Meredith, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 16, 2008
First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates
Sethu Sankaranarayanan, Marie A Holahan, Dennis Colussi, et al.
Page
of 4